Echinocandins are effective in patients with invasive candidiasis and recommended as first-line therapy, especially for patients with severe sepsis or those previously exposed to azoles or infected with *Candida glabrata* ([@R1]). Fewer than 50 persons infected with echinocandin-resistant species that are usually susceptible, such as *C. albicans*, *C. glabrata*, *C. tropicalis*, and *C. krusei*, have been described in limited series or case reports ([@R2]*--*[@R4]). All species were found in patients preexposed to echinocandins. The major mechanism of resistance is related to mutations in *FKS* genes coding for β-1,3-glucan-synthase ([@R5]), with almost 20 known *FKS* mutations. We describe the characteristics of infections from caspofungin-resistant *Candida* spp. isolates belonging to usually susceptible species recorded in France (2004--2010) and analyze their *FKS* mutations and effect on echinocandin susceptibility.

The Study
=========

Isolates received at the French National Reference Center for Mycoses and Antifungals (NRCMA) are identified to the species level by standard mycologic procedures and routinely tested for susceptibility to caspofungin, micafungin, and anidulafungin by using European Committee for Antimicrobial Susceptibility Testing (EUCAST) methods ([@R6]) and AM3 medium ([@R7]). In addition, RPMI 1640 medium was used here for selected isolates and reference strains. For the clinical isolates with caspofungin MIC [\>]{.ul}0.5 µg/mL in AM3, nucleotide sequences of hot spot (HS) 1 and 2 regions of the *FKS1* gene for *C. albicans* and *C. krusei* and of HS1 region of *FKS1*, *FKS2*, and *FKS3* genes for *C. glabrata* were determined ([@R7]*,*[@R8]).

The resulting protein sequences were aligned with the BioloMics software (BioloMics, BioAware SA, Hannut, Belgium) and compared with reference strains (*C. albicans*, ATCC32354; *C. krusei*, ATCC6258; and *C. glabrata*, ATCC2001). Genetic relatedness of *C. albicans* and *C. glabrata* paired isolates was studied by using microsatellite-length polymorphism analysis ([@R9]*--*[@R11]). The Wilcoxon signed-rank test was used to compare echinocandin MICs of paired isolates. Surveillance for mycoses by the NRCMA has been approved by the Institut Pasteur Internal Review Board and by the Commission Nationale de l'Informatique et des Libertés.

During September 2004--April 2010, twenty proven infections caused by *C. albicans* (n = 10), *C. glabrata* (n = 8), or *C. krusei* (n = 2) with caspofungin MIC [\>]{.ul}0.5 µg/mL and a mutation in the target enzyme were reported to the NRCMA ([Table 1](#T1){ref-type="table"}). Nineteen of the isolates were recovered after caspofungin treatment for a median duration of 27 days (range 10--270 days; 13 of 19 patients received caspofungin at the time the resistant isolate was recovered). Caspofungin was prescribed for 14 patients with proven *Candida* spp. infection, 1 patient with proven invasive aspergillosis, and 2 patients with febrile neutropenia; for 2 persons with hematologic malignancies, caspofungin was prescribed prophylactically.

###### Characteristics of 20 patients with infections caused by a non--*parapsilosis/guilliermondii Candida* spp. Fks mutation, France, 2004--2010\*

  Patient no.   Age, y/sex   Underlying condition                                   Neutropenia   Species         Site of infection                  Duration of caspofungin exposure, d†   Outcome at 30 d‡
  ------------- ------------ ------------------------------------------------------ ------------- --------------- ---------------------------------- -------------------------------------- ------------------
  1             34/M         HIV positive                                           No            *C. albicans*   Esophagus                          21                                     Alive
  2             20/M         Hematologic malignancy: familial lymphohistiocytosis   Yes           *C. albicans*   Blood                              17                                     Dead
  3             77/M         Hematologic malignancy: AML                            Yes           *C. albicans*   Blood                              25                                     Alive
  4             46/M         Hematologic malignancy: AML                            Yes           *C. albicans*   Blood, peritoneum, pleural fluid   26                                     Dead
  5             34/F         Liver transplant: cirrhosis                            No            *C. albicans*   Hepatic abscess, peritoneum        60                                     Alive
  6             64/F         Hematologic malignancy: AML; breast cancer             No            *C. albicans*   Blood                              25                                     Alive at 17 d
  7             59/M         Teratocarcinoma                                        No            *C. albicans*   Pharynx                            35                                     Dead
  8             28/M         Chronic mucocutaneous candidiasis                      No            *C. albicans*   Pharynx, nails                     270                                    Alive
  9             14/F         Hematologic malignancy: ALL                            Yes           *C. krusei*     Lung                               45                                     Alive
  10            79/M         Hematologic malignancy: non-Hodgkin lymphoma           Yes           *C. krusei*     Blood                              10                                     Dead
  11            46/M         Hematologic malignancy: Burkitt lymphoma; HSCT         Yes           *C. glabrata*   Blood                              None                                   Dead
  12            85/M         Gastric ulcer; CVC                                     No            *C. glabrata*   Blood                              32                                     Alive
  13            28/M         Hematologic malignancy: non-Hodgkin lymphoma; HSCT     No            *C. glabrata*   Palate§                            135                                    Alive
  14            48/M         Esophageal cancer                                      No            *C. glabrata*   Blood                              12                                     Alive
  15            41/M         Liver transplant: fulminant hepatitis                  No            *C. glabrata*   Blood, peritoneum                  37                                     Dead
  16            38/F         Hematologic malignancy; AML; HSCT                      Yes           *C. glabrata*   Blood                              51                                     Dead
  17            60/M         Acute pancreatitis; GI tract surgery                   No            *C. glabrata*   Bile                               34                                     Alive
  18            39/M         Hematologic malignancy: AML; HSCT                      No            *C. glabrata*   Sinus§                             15                                     Alive
  19            55/F         Lock-in syndrome; neurogenic bladder                   No            *C. glabrata*   Urine¶                             27                                     Alive
  20            63/M         Colon cancer                                           Yes           *C. glabrata*   Blood                              14                                     Alive

\*AML, acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; HSCT, hematopoietic stem cell transplantation; CVC, central venous catheter; GI, gastrointestinal. †Duration of caspofungin exposure before isolation of the first resistant *Candida* isolate. ‡Outcome 30 d after isolation of the first resistant *Candida* isolate. §From a biopsy specimen. ¶With sepsis.

The geometric mean MIC for *C. glabrata* and *C. albicans* were 2.8 and 1.7 µg/mL for caspofungin, 0.4 and 0.7 µg/mL for micafungin, and 0.2 and 0.09 µg/mL for anidulafungin, respectively ([Table 2](#T2){ref-type="table"}). Of the 20 mutated isolates found resistant to caspofungin in AM3 by using the EUCAST method, 19 also were resistant to caspofungin (1 intermediate), 18 to micafungin (1 intermediate and 1 susceptible), and 9 to anidulafungin (5 intermediate and 6 susceptible) according to Clinical Laboratory Standards Institute (CLSI) breakpoints and RPMI 1640 medium ([Table 2](#T2){ref-type="table"}). According to EUCAST breakpoints, 19 isolates also were resistant to anidulafungin, and 1 isolate was almost resistant (MIC 0.03 µg/mL). We thus showed discrepancies between CLSI and EUCAST regarding anidulafungin susceptibility ([www.srga.org/eucastwt/MICTAB/EUCAST%20clinical%20MIC%20breakpoints%20-%20antimicrobials%20for%20Candida%20infections.htm](http://www.srga.org/eucastwt/MICTAB/EUCAST%20clinical%20MIC%20breakpoints%20-%20antimicrobials%20for%20Candida%20infections.htm) \[V 3.0 2011--4-27\]) ([@R12],[@R13]).

###### In vitro susceptibility and Fksp mutations of 20 echinocandin-resistant *Candida* spp. isolates, France, 2004--2010

  Patient no.   Strain       Species         MIC, µg/m, AM3/RPMI 1640 medium               Fksp mutation                        
  ------------- ------------ --------------- --------------------------------- ----------- --------------- -- ----------------- -----------------------------------
  Caspofungin   Micafungin   Anidulafungin   Gene                              Mutation                                         
  1\*           05BL1-38     *C. albicans*   1/2                               0.25/1      0.06/0.125         *FKS1* (HS1)      F641S
  2\*           ODL13-1254   *C. albicans*   1/2                               1/1         0.5/0.5            *FKS1* (HS1)      S645Y
  3†            06BL2-127    *C. albicans*   2/2                               1/0.5       0.125/0.125        *FKS1* (HS1)      F641S‡ + S645P‡
  4             ODL19-1894   *C. albicans*   4/2                               2/2         0.125/0.25         *FKS1* (HS1)      S645P
  5\*           08BL1-94     *C. albicans*   2/4                               0.25/1      0.06/0.5           *FKS1* (HS2)      R1361G§
  6\*           08BL2-143    *C. albicans*   8/4                               4/2         0.25/0.5           *FKS1* (HS1)      S645P
  7\*           09BL1-43     *C. albicans*   1/2                               0.25/1      0.06/0.25          *FKS1* (HS1)      F641S
  8\*           09BL1-77     *C. albicans*   0.5/0.5                           0.5/0.25    0.015/0.03         *FKS1* (HS1)      R647G§
  9             06BL1-34     *C. krusei*     4/8                               2/4         1/2                *FKS1* (HS1)      L648W§,¶
  10\*          10BL1-50     *C. krusei*     2/4                               1/2         0.06/1             *FKS1* (HS1)      F645L§,¶
  11            ODL7-647     *C. glabrata*   8/8                               0.5/1       0.25/0.125         *FKS2*            DelF658\#
  12\*          07BL2-157    *C. glabrata*   4/1                               1/0.5       0.25/0.5           *FKS2*            DelF658\#
  13\*          06BL1-33     *C. glabrata*   8/8                               4/8         2/2                *FKS2*            S663P
  14\*          ODL21-2028   *C. glabrata*   1/1                               0.25/0.25   0.25/0.25          *FKS1*            S629P
  15\*          ODL22-2183   *C. glabrata*   8/2                               0.25/0.25   0.25/1             *FKS2*            S663P
  16            ODL23-2221   *C. glabrata*   1/4                               0.06/2      0.06/0.25          *FKS1* + *FKS2*   F625I§ (*FKS1*) + P667T§ (*FKS2*)
  17\*          08BL2-142    *C. glabrata*   1/4                               0.25/2      0.25/2             *FKS2*            S663P
  18            09BL1-55     *C. glabrata*   8/4                               2/4         0.5/0.5            *FKS2*            S663P
  19            10BL1-19     *C. glabrata*   0.5/4                             0.06/0.5    0.06/1             *FKS2*            F659S + L664V§
  20            10BL1-67     *C. glabrata*   4/4                               0.5/1       0.125/1            *FKS2*            DelF658\#

\*Parentage of initial isolate available. †In this patient, another isolate with reduced susceptibility to echinocandin was retrieved. This isolate harbored an S645P mutation in *FKS1*. ‡Heterozygous mutation. §Mutations not already described ([@R13]). ¶Strains had also an L701M mutation. \#Deletion.

Of the 10 caspofungin-resistant *C. glabrata* isolates, 8 harbored a mutation in Fks2p only, 1 isolate had a mutation in Fks1p, and 1 had mutations in Fks1p and Fks2p ([Table 2](#T2){ref-type="table"}). Of the 8 caspofungin-resistant *C. albicans* isolates, 1 had a missense mutation in HS2, and 1 had a combination of 2 heterozygous mutations in HS1. The other 6 isolates harbored 4 different mutations in HS1 ([Table 2](#T2){ref-type="table"}). Finally, the 2 *C. krusei* isolates had 2 different mutations in HS1 region. Of the 20 mutated isolates, 6 harbored 7 mutations not yet described in the literature ([Table 2](#T2){ref-type="table"}) ([@R13]).

Prior initial isolates available for 12 patients had the wild-type sequence for the HS regions that were mutated in the paired resistant isolate. All initial isolates were susceptible to anidulafungin and to micafungin and anidulafungin according to EUCAST and CLSI, respectively (data not shown). According to CLSI caspofungin breakpoints, 5 of 6 initial isolates of *C. albicans* were susceptible, and 1 was intermediate; 4 of 5 *C. glabrata* isolates were resistant (0.5 µg/mL), and 1 was intermediate; and the *C. krusei* isolate was resistant (1 µg/mL). For each of the 12 pairs, MICs increased significantly (from 3 to 8 dilutions for caspofungin and micafungin and from 1 to 8 dilutions for anidulafungin) between the wild-type and the mutant isolate ([Figure](#F1){ref-type="fig"}; p\<0.001). Genetic relatedness was demonstrated for all *C. albicans* and *C. glabrata* paired isolates.

![Corresponding caspofungin (A), micafungin (B), and anidulafungin (C) MICs in 12 Fksp mutant *Candida* spp. isolates and their wild-type parent isolates, France, 2004--2010. Susceptibility testing was performed by using the European Committee for Antimicrobial Susceptibility Testing method ([@R6]) and AM3 medium ([@R7]).](11-0556-F){#F1}

Conclusions
===========

We demonstrated that recent exposure to caspofungin altered the distribution of species causing *Candida* bloodstream infections ([@R14]), and that caspofungin exposure was independently associated with fungemia associated with intrinsically less-susceptible species in hematology ([@R15]). Echinocandin resistance in *Candida* spp. is still uncommon ([@R4]*,*[@R13]). Through our surveillance program, we estimated the incidence of decreased susceptibility to caspofungin associated with *FKS* mutations among *C. albicans, C. glabrata*, and *C. krusei* isolates responsible for candidemia in children and adults in Paris at 6 (0.4%) of 1,643 (NRCMA, unpub. data). We report proven caspofungin-resistant *Candida* spp. infections with none of the isolates belonging to the intrinsically less-susceptible species *C. parapsilosis* or *C. guilliermondii*.

We determined antifungal susceptibility testing by the EUCAST technique using AM3 because it enables better discrimination between susceptible wild-type and resistant mutant isolates ([@R7]). All isolates with high caspofungin MIC ([\>]{.ul}0.5 µg/mL) had mutation in the HS1 and/or HS2 region of *FKS* genes. The mutations were not restricted to a given position but were diverse, especially for *C. albicans* with 6 different mutations among the 8 resistant isolates; 5 different mutations were observed among the 10 *C. glabrata* resistant isolates. Most mutations in *C. glabrata* isolates were in Fks2p. Two mutations in *C. albicans*, 2 patterns of mutation in *C. glabrata*, and 1 mutation in *C. krusei* had not been reported before, highlighting the great mutation diversity that could be responsible for echinocandin resistance ([@R13]).

All but 1 patient had received caspofungin (70 mg on day 1, then 50 mg/d) before recovery of the resistant isolate, with a variable duration of exposure (\<10 days to \>8 months), in agreement with the literature (5 \[[@R3]\] to 420 days). In addition, 13 of 19 patients received caspofungin at the time of recovery of the resistant isolate. Most patients had malignancy, but 7 intensive care unit hospitalizations also were recorded. Echinocandins MICs between the wild-type parent and the subsequent mutant isolate increased by up to 8 log~2~ dilutions ([Figure](#F1){ref-type="fig"}). The source of the resistant isolate is not unequivocal; it was acquired from the environment as an already resistant isolate or from the patient's own flora under drug pressure. Our genotyping results favor the second hypothesis. This study suggests in France the emergence of infections from acquired echinocandin resistance in usually susceptible *Candida* spp. in patients preexposed to caspofungin, which highlights the need for careful species identification, antifungal drug susceptibility testing, and evaluation of prior drug exposure before antifungal drug prescription.
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